Académique Documents
Professionnel Documents
Culture Documents
in Diagnosis and
Tre a t m e n t o f
Rheumatoid Arthritis
James T. Birch Jr,
MD, MSPH*,
Shelley Bhattacharya,
DO, MPH
KEYWORDS
Rheumatoid arthritis Juvenile rheumatoid arthritis
Disease-modifying antirheumatic drugs Synovitis
Elderly onset rheumatoid arthritis
EPIDEMIOLOGY
Rheumatoid arthritis (RA) is a chronic inflammatory disease with multiple comorbidities and is a cause of disability for many children and adults worldwide. The role of
primary care is essential in early diagnosis and treatment of this debilitating disease.
The prevalence of RA is estimated to be 0.8% globally, with women 2 to 4 times as
likely as men to develop the disease. The incidence of RA in the United States is estimated at 25 per 100,000 men and 54 per 100,000 women, affecting approximately 2.1
million people.1,2 Age at onset is usually between 30 and 50 years of age; however,
juvenile RA and elderly onset RA (over age 65) also occur.1,2
In the United States, arthritis and other rheumatic conditions are the leading cause
of disability. Approximately 39% of adults with arthritis report limitations in their physical activities because of their condition. Patients with RA are more than 7 times as
likely to have greater than moderate disability as their sex- or age-matched counterparts. In addition, RA disability is linked with increased mortality. The Health Assessment Questionnaire (HAQ) disability index used to follow RA patients found that
a change of 1 standard deviation in the HAQ correlates to an odds ratio for mortality
of 2.3.2 After 10 to 20 years of having the disease, as many as 80% show a compromise of their activities of daily living. Beginning early treatment can reduce the potential for disability by more than 60%.3
In economic terms, RA accounts for an estimated 250,000 hospitalizations and 9
million physician office visits annually. Within 2 to 3 years of diagnosis, 20% to 30%
780
of those with RA become permanently disabled from work because of pain, impaired
physical function, and transportation difficulties.1,2 The total costs of arthritis and other
rheumatologic conditions in the United States in 2003 was $128 billion ($80.8 billion
from direct medical costs and $47 billion from indirect costs such as lost earnings).
In addition, a reduced life expectancy of 5 to 15 years can occur.3
RISK FACTORS
Several environmental and genetic factors that potentially contribute to increased risk
of developing RA have been identified. There are no definitive risk factors.
Environmental factors include hormonal exposure, tobacco use, microbial exposure, smoking, and consumption of more than 3 cups of decaffeinated coffee daily.1,4
Among these, tobacco use has the most consistent evidence for an association.4
Genetic factors include female gender, positive family history, older age, and the
HLA genotype.1,4 In monozygotic twins, the concordance rate for the development
of RA is more than 30%.1 Siblings of patients with the disease are 2 to 4 times
more likely to develop the disease than persons who are not related.3 Among whites
who have RA, 80% express the HLA-DR1 or HLA-DR4 subtypes.1
Risk of RA is reduced through high vitamin D intake, tea consumption, use of oral
contraceptives, and with breast-feeding.1 Women who have never given birth seem
to have a slight to moderate risk of developing RA, and the evidence is mixed
regarding an association between RA and hormone replacement therapy.1
PATHOPHYSIOLOGY
The pathophysiology of RA essentially remains only partially understood. A complicated interaction between environmental and genetic factors eventually results in
the onset of disease. A viral infection or other biologic factor can initiate an abnormal
autoimmune inflammatory response in persons who are genetically predisposed to
RA. Where chronic inflammation exists in these cases of RA, there is an imbalance
among the mediators controlling the systems response, resulting in eventual damage
to cartilage and bone.5 The pathophysiology of RA originates with inflammation of
the synovium at any joint location, possibly triggered by the presentation of an antigen,
autoantigen, or athrogenic peptide to the immune system. It appears that the subsequent cascade of inflammatory responses leads to proliferation of synovial macrophages, fibroblasts, and chondrocytes in the articular cartilage. These cells secrete
enzymes that degrade proteoglycans and collagen, which eventually precipitate synovial tissue destruction.5 Further infiltration by lymphocytes and other inflammatory
cells occurs and is accompanied by angiogenesis in the synovium, causing irregular
regrowth of the synovial tissue and eventually forming invasive pannus tissue. This
process stimulates the increased activity of osteoclasts, resulting in further inflammation, leading to more cartilage destruction and the characteristic bony erosion of RA
(Fig. 1).1 Continued ongoing release of inflammatory mediators along with interleukins,
tumor necrosis factor a (TNFa), cytokines, and proteinases, also contributes to the
development of systemic symptoms and the extra-articular manifestations of RA.1,5
There is suspected to be a shared epitope, possibly derived from the disease-associated HLA-DR4/1 allele that is initially presented by an antigen-presenting cell to the T
cell as a self-antigen.6 Later in life, these T cells could be activated by cross-reactive
antigens that display the shared epitope, leading to the inflammatory cascade.6
Multiple infectious agents are known to possess potentially cross-reactive peptides
so that possible reactivation of RA by these common and ubiquitous organisms might
occur.6
Fig. 1. Pathogenesis of RA. (Reprinted from Pope RM. Apoptosis as a therapeutic tool in
rheumatoid arthritis. Nat Rev Immunol 2002;2(7):52735; with permission from Nature
Publishing Group.)
781
782
DIAGNOSIS
No single test confirms the diagnosis of RA. Diagnosis is largely based on clinical findings and patient history, which is challenging because the symptoms are similar to
many other potential causes of joint inflammation and pain.3 There are several tests
that can be used to increase diagnostic probability and monitor disease progression.
It is imperative that a diagnosis be established as early as possible, because a delay as
much as 4 to 6 months in initiation of treatment could result in long-term joint injury.5
In 1987, the American College of Rheumatology (ACR), in conjunction with the
American Rheumatism Association, established 7 diagnostic criteria to aid in the clinical diagnosis of RA.5 These criteria are also used to define RA in epidemiologic
studies.4 Any patient who presents with at least 4 of the listed criteria for 6 weeks
or longer is considered to have RA (Table 1).7 Early RA is the classification of disease
that is diagnosed within 6 months of symptom onset. There is considerable focus in
this area because early treatment has been demonstrated to have a positive impact
on disease progression and prognosis.4
Efficient diagnosis of RA requires vigilant attention to the patients medical history.3
Signs of early synovitis in the absence of obvious joint deformity might be uncovered
by the squeeze test of the metacarpophalangeal (MCP) joints or the metatarsophalangeal (MTP) joints.3 A key sign of RA at the time of the onset is symmetric joint swelling
Table 1
1987 Criteria for the classification of acute arthritis of RA
Criterion
Definition
Morning stiffness
Arthritis of 3 or more
joint areas
Symmetric arthritis
Rheumatoid nodules
Serum RF
Radiographic changes
For classification purposes, a patient shall be said to have RA if he or she has satisfied at least 4 or
these 7 criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients with 2
clinical diagnoses are not excluded. Designation as classic, definite, or probable RA is not to be
made.
Abbreviations: MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal; RF, rheumatoid factor.
Adapted form Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1998;31(3):31524;
with permission.
with local heat and erythema. In the early phase there is usually no clinical evidence of
joint disease and no evidence of cartilage or bone loss on plain radiographs. The
physician or diagnostic clinician also needs to evaluate the patient for extra-articular
features of RA, which will determine the potential course of the disease and guide
treatment options.3
SYMPTOMS
Patients with RA typically present with pain and stiffness in multiple joints. However,
one-third of patients have initial symptoms at a solitary location. The most common
presentation of RA is that of an insidious onset of morning stiffness or diffuse aching
that lasts for at least 1 hour or longer, followed by involvement of the small peripheral
joints such as the MCP, MTP, and proximal interphalangeal (PIP).3 It is not unusual for
the larger joints to be affected first. Symptoms usually occur over weeks to months,
yet in 15% of patients onset can occur more rapidly over days to weeks. Most patients
have accompanying prodromal symptoms of weakness, fatigue, or anorexia. In 8% to
15% of patients, symptoms begin soon after a trigger event, such as a viral illness.1
Characterizing the pain often helps distinguish RA from other forms of arthritis, as
does a positive family history for RA. Determination of disability and ability to perform
activities of daily living facilitates monitoring the effects of treatment.
The joints that are usually affected are those with the highest ratio of synovium to
articular cartilage, such as the wrist, PIP, and MCP joints. The distal interphalangeal
and sacroiliac joints are usually not affected. Affected joints are usually warm, tender
to palpation, and boggy. There might be increased blood flow to the inflamed area with
subsequent symptoms of puffy hands by patients.1 Joint swelling is usually symmetric
and, with tenderness on palpation, is one of the key signs of RA.2 Beyond the joints,
axillary, cervical, or epitrochlear lymphadenopathy may be noted. Muscles in close
proximity to the inflamed joints often atrophy. Weakness is commonly out of proportion to the pain on examination. Joints are often held in flexion by patients to minimize
painful distension of the joint capsules. Clinically, one may also appreciate decreased
grip strength from tendon damage, tendon rupture in the wrist and fingers, decreased
range of motion in the shoulders from synovitis and anterior effusions, and heel pain
with antalgia from talus involvement. The hip is usually affected later, and hip involvement is usually rare.3
LABORATORY TESTS
Indications for testing include a history of persistent joint pain with early morning stiffness. Baseline laboratory tests are recommended and include a complete blood cell
count with differential, rheumatoid factor (RF), and erythrocyte sedimentation rate
(ESR) greater than 30 mm/h or C-reactive protein (CRP) greater than 0.7 pg/mL. Renal
and hepatic function parameters are also recommended because findings guide
medication choices, and monitoring should continue throughout the course of
treatment.1
RF is an immune complex consisting of an autoantibody and IgG. A positive RF is
not diagnostic of RA. Incidence of positivity increases with duration of disease (ie,
612 months), and with age. Of patients with RA, 20% may never have a positive
RF, approximately 5% to 10% of healthy individuals are RF positive, and RF might
also be positive in many other disease processes.1,8
Other laboratory tests that aid in the diagnosis of RA are as follows.
783
784
When positive, this test supports the diagnosis of RA. It is produced in the first stage of
RA pathogenesis at the site of joint inflammation. During this process, citrullination of
synovial antigens occurs, involving several synovial proteins. The antibody, anticyclic
citrullinated peptide (anti-CCP), is secreted by B cells, which are present in the synovium and bone marrow of anti-CCPpositive patients.9 Anti-CCP is more than 98%
specific, and sensitivity increases when used in combination with RF. It might be negative during the course of early disease. One study found the anti-CCP antibody to be
associated with some parameters of disease activity and severity, being more specific
in patients with advanced RA with a mean duration of 9.8 years.10
Arthrocentesis (Joint Aspiration)
This option is a useful one if the diagnosis is uncertain. Arthrocentesis helps to differentiate crystal-induced arthropathies and septic arthritis. In RA, fluid is usually strawcolored, and fibrin flecks are often seen; clotting may occur at room temperature;
a white blood cell count of 5 to 25,000 per mm3 is common, with a differential count
of 85% polymorphonuclear leukocytes. Findings also include no crystals, low glucose
levels, and negative cultures.1,8 Synovial fluid evaluation for anti-CCP has been suggested by a study to be a useful tool to assist with diagnosis of RA in cases of undifferentiated arthritis. The presence of anti-CCP in synovial fluid is a high risk factor for
progression to RA.9 Some patients may have negative serum levels when the joint fluid
is positive.9
Plain Film Radiography
Plain film radiography remains the preferred method for initial examination to evaluate
bone and soft tissue changes. Although a definite diagnosis might not be possible,
even subtle findings and evaluation of soft tissue changes can facilitate a differential
diagnosis. Depending on the severity of the disease, radiography can reveal soft tissue
swelling and joint space narrowing as a consequence of cartilage thinning, or joint
space widening as an indication of joint effusion. Juxta-articular osteoporosis is
also one of the nonspecific changes that can confirm the clinical impression of an
inflammatory process.11
EXTRA-ARTICULAR SIGNS AND SYMPTOMS
Children are not exempt from the disease of RA. The true incidence is unknown.12 A
2007 study by the Centers for Disease Control and Prevention estimates that
Box 1
Extra-articular manifestations of RA
Rheumatoid nodules of varying size and consistency are found in up to 25% of patients.
Location: extensor area of the forearm (common), internal organs (rare). Complications:
gangrene and ulcer formation.
Hematologic: normocytic, normochromic anemia; thrombocytosis or thrombocytopenia;
lymphadenopathy.
Felty syndrome: the association of RA with leukopenia and splenomegaly
Vasculitis: may involve eyes, brain, skin, renal, cardiovascular, and gastrointestinal (GI) tract
Pulmonary: pleural effusions, pulmonary nodules, interstitial lung disease, bronchiolitis
obliterans with organizing pneumonia; complications of treatment with disease-modifying
antirheumatic drugs (DMARDs)
Cardiac: pericardial effusions; valvular lesions; cardiac manifestations from systemic influences
of RA such as serositis, amyloidosis, vasculitis, conduction abnormalities secondary to nodule
formation
Renal: microalbuminuria (correlates with disease activity); mesangial glomerulonephritis;
(nephritic syndrome); nephrotoxicity secondary to DMARDs
Ophthalmologic: keratoconjunctivitis sicca or secondary Sjogren syndrome; episcleritis and
scleritis (prompt treatment necessary to avert vision loss); effect of drug therapyrisk of
retinopathy with hydroxychloroquine requires ongoing surveillance
Neurologic: mononeuritis multiplex and central nervous system features including seizures,
aseptic meningitis, and stroke secondary to vasculitis. Entrapment neuropathies via nerve
impingement associated with subluxation of the atlantoaxial joint, amyloid deposits, or
nodules
Musculoskeletal: osteoporosis and fractures caused by disease process and corticosteroid
treatment. Muscular weakness of varying etiology
Amyloidosis: found in 21% of patients in postmortem studies of patients with RA
Data from Firestein GS, Panayi GS, Wollheim FA. Rheumatoid arthritis: frontiers in pathogenesis
and treatment. New York: Oxford University Press; 2000.
294,000 children in the United States younger than of 18 years (1 in 250) have been
diagnosed with arthritis or another rheumatologic condition.13 The most common
form of childhood arthritis is juvenile rheumatoid arthritis (JRA).13 The American Rheumatism Association acknowledges 3 clinical classifications of JRA: systemic-onset
disease (10%20%), polyarticular disease (20%40%), and pauciarticular disease
(30%40%).12 Clinical symptoms are varied in each category and each type has its
own unique presentation, clinical course, and immunogenetic association. The
polyarticular and pauciarticular forms contain more than 1 subgroup (Polyarticular:
RF-negative and RF-positive disease; Pauciarticular: early childhood onset and late
childhood onset).12 Recognition of the subgroups is important for the appropriate
diagnosis and treatment of the younger JRA patient.12 One feature that all JRA
patients have in common is the presence of chronic synovitis.
Once treatment is initiated, children should be encouraged to lead full lives as much
as possible. Occasionally, some may be disabled or too ill to be self-sufficient and
require inpatient rehabilitation. Support and counseling is necessary to prevent educational deficits, provide support of career plans, and in general to prevent children from
thinking of themselves as people with disability.12
785
786
Currently 75% to 80% of children with JRA are expected to survive the disease
without disability.12 Those at greatest risk for joint destruction are those with
systemic-onset JRA and RF-positive polyarthritis. Careful follow-up is necessary for
all JRA patients throughout the course of active disease, and there is always the possibility of unexpected recurrences even after years of remission.12 However, the future
remains positive for most affected children.
ELDERLY ONSET RA
Elderly onset rheumatoid arthritis (EORA) includes patients who develop RA between
the age of 60 and 65 years. The prevalence is approximately 2% in this age group.14
Symptoms of EORA are different from those in younger patients, and 3 subsets have
been identified14:
1. Patients who have classic RA signs and symptoms with clinical onset similar to that
in patients who develop seropositive RA at an earlier age. These patients have high
levels of disease activity, and aggressive treatment is required.14
2. Patients presenting with symmetric arthritis associated with Sjogren syndrome.
The synovitis is less severe and more readily controlled than in the first subset.14
3. Patients have a clinical picture that mimics polymyalgia rheumatica. RF is negative
in the vast majority of cases but high levels of acute phase reactants are present.
Arthritis in this subset of patients is usually well controlled with low-dose corticosteroid treatment; joint damage and radiological changes are less severe than in the
other forms.14
EORA occurs in a balanced female to male ratio of about 1.5:1 to 2:1.14 Poorer functional outcomes have been noted in patients who score high on the HAQ and who have
RF seropositivity.14 However, overall, EORA patients are more likely to experience
clinical remission (odds ratio [OR] 5 2.99) with a much higher remission rate in the
seronegative EORA group than all other groups (including the younger seronegative
RA group). It should also be noted that continuous use of corticosteroids for more
than 3 months in EORA patients has been associated with joint erosion (OR 5 4.09).
Diagnosis of EORA requires early and appropriate initiation of DMARD therapy no
different from that given to younger RA patients. The higher remission rate in seronegative EORA patients implies that therapy might be given for a shorter duration than for
seropositive patients. Awareness should be heightened regarding the increased risk of
adverse events associated with RA treatments in the elderly patient. Careful follow-up
and prudent use of the appropriate medications is extremely important.14
DIFFERENTIAL DIAGNOSIS
Table 2
Differential diagnosis of RA
Connective tissue diseases
Fibromyalgia
Other forms of arthritis (infectious, reactive,
viral, osteoarthritis)
Seronegative spondyloarthropathies
Sarcoidosis
Hemochromatosis
Infectious carditis
TREATMENT
Early treatment reduces the rate of disease progression and is therefore recommended to be initiated during the early phase of the disease.1 Many patients experience
RA symptoms for an average of 9 to 12 months before a diagnosis is made.2 The
American College of Rheumatology Subcommittee on Rheumatoid Arthritis (ACRSRA)
recommends that patients with suspected RA be referred to a rheumatologist within 3
months of presentation to confirm the diagnosis and initiate treatment. The National
Guideline Clearinghouse also supports specialist referral and recommends urgent
referral if the small joints of the hands or feet are affected, more than 1 joint is affected,
or there has been a delay of 3 months or more between the onset of symptoms and
seeking of medical advice.15 Therapeutic goals must be discussed with the patient
and should include preservation of quality of life, reducing pain, minimizing inflammation, protecting the joints, and reducing RA complications.1
Patients with mild disease and normal radiograph joint findings can begin treatment
with hydroxychloroquine, sulfasalazine, minocycline, or methotrexate.1,16 Fig. 2
contains an algorithm that simplifies the approach to treatment.1 Nonsteroidal antiinflammatory drugs (NSAIDs) should not be used alone, as they do not change the
disease course. Precautions should be observed with NSAID use, as RA patients
are almost twice as likely as osteoarthritis patients to have serious complications
from NSAID use.
Cyclooxygenase-2 (COX-2) selective NSAIDs are equally as effective as nonselective NSAIDs for reducing pain and inflammation as well as improving joint function.
These agents should be used with caution in renal and geriatric patients.1 There is
also ongoing concern of the cardiovascular safety of COX-2 NSAIDs. Therefore, careful patient selection is imperative. There have been long-term studies, such as the
CLASS study (Celecoxib Long-term Arthritis Safety Study), which showed a reduction
in adverse upper GI events in patients taking celecoxib alone without low-dose aspirin
versus NSAIDs alone or COX-1 versus COX-2 NSAIDs with low-dose aspirin.17 Owing
to the cardiac benefit of low-dose aspirin for patients with moderate or high
787
788
Yes
No
Mild disease
Fig. 2. Treatment algorithm for RA. aThe following laboratory tests should be performed
before methotrexate therapy begins, every 2 weeks for 6 weeks, then, if normal, every 2
months: complete blood count with differential, platelets, aspartate transaminase levels,
albumin levels, and creatinine levels. When starting methotrexate add 1 mg oral folic
acid per day to decrease side effects, and caution the patient to avoid alcohol. bWhen adding another DMARD to methotrexate, decrease the dosage of methotrexate to 10 to 15 mg
once per week. (Reprinted from Rindfleisch JA, D Muller. Diagnosis and management of
rheumatoid arthritis. Am Fam Physician 2005;72(6):1042; with permission.)
789
790
recommended for patients with moderate to high disease activity, regardless of duration or presence of poor prognostic features. Methotrexate plus sulfasalazine is recommended in patients with all durations if they have high disease activity and poor
prognostic features. Hydroxychloroquine plus sulfasalazine is recommended only in
patients with 6 to 24 months of disease duration and with high disease activity yet
without poor prognostic features.16
Triple DMARD combination therapy of sulfasalazine plus hydroxychloroquine plus
methotrexate is recommended for all patients with poor prognostic features and
moderate to high levels of disease activity, regardless of duration of disease.
Regarding biologic DMARDs (anti-TNFa agents), the ACR recommendations are
divided into those with RA for lass than 6 months and those with RA for longer than
6 months. The anti-TNFa agents are efficacious in improving disease activity, function,
and quality of life when used alone or in combination with methotrexate or other nonbiologic DMARDs. Recommendations for the use of anti-TNFa agents with methotrexate are limited only to patients with early RA who have never received DMARDs,
have had high disease activity for lass than 3 months, a poor prognosis, and without
cost restrictions. In those with longer RA duration, the ACR recommends the use of
anti-TNFa agents in patients for whom methotrexate monotherapy or combination
therapy with nonbiologic DMARDs was inadequate.16
The risk of death from infection in patients with RA is approximately 6 to 9 times
greater than in non-RA populations.20 Risk factors for infections include corticosteroid
therapy, comorbidities, skin breakdown, joint surgery, and established RA. Nonbiologic and biologic DMARDs and TNF antagonists may place patients at greater risk
of infection. Therefore, when a fever presents in an RA patient, sepsis should be
strongly considered and a rheumatologist should be consulted early during the initiation of care. However, patients on a DMARD and steroids may not mount a typical
febrile response; therefore a thorough clinical examination is necessary, including
a thorough joint examination in which joint pain might be the most significant sign of
infection.20
The ACR recommends routine tuberculosis (TB) screening for all patients who are
being considered for treatment with biologic DMARDs. This recommendation is based
on the evidence of higher incidence of TB cases following the initiation of anti-TNFa
therapy. All patients should be asked about their risk factors for TB. A negative TB
skin test should not be considered an exclusion of latent TB infection because
many RA patients are immunosuppressed. In cases of active or latent TB, antiTNFa therapy can be started about 1 month after initiating anti-TB therapy with
isoniazid.16
Contraindications to DMARD use include active bacterial infection requiring antibiotic therapy, active TB (untreated), active herpes zoster infection, RA-associated
pneumonitis, or active life-threatening fungal infections. In addition, the ACR recommends against the use of biologic agents during a severe bacterial or viral upper respiratory infection. Each DMARD has its own monitoring requirements and
contraindications that are discussed elsewhere.
Safety ratings vary for use of RA therapies during pregnancy. Methotrexate and
leflunomide have been issued a safety rating X by the Food and Drug Administration.
Safety ratings for other treatments include B for sulfasalazine, C or D for other nonbiologic DMARDs, and B or C for biologic DMARDS.
Several novel therapies have also been studied for RA. Statins (atorvastatin and pravastatin) may have anti-inflammatory properties in the synovium, with an ability to
inhibit both the production and actions of CRP.21 Other novel therapies that are being
studied for the treatment of RA include hematopoietic stem cell transplantation and
791
792